27494906|t|Impact of AAC(6')-Ib-cr in combination with chromosomal -mediated mechanisms on clinical quinolone resistance in Escherichia coli
27494906|a|aac(6')-Ib-cr is the most prevalent plasmid -mediated fluoroquinolone (FQ) resistance mechanism in Enterobacteriaceae. We aimed to analyse the interplay between this plasmid -mediated gene and chromosomal -mediated quinolone resistance mechanisms on both FQ resistance and bacterial fitness in Escherichia coli. E. coli ATCC 25922 and derived isogenic strains carrying chromosomal -mediated quinolone resistance modifications (Ser83Leu-Asp87Asn in GyrA, Ser80Arg in ParC and/or a marR gene deletion) were electroporated with a pBK-CMV vector encoding AAC(6')-Ib-cr. The MICs of FQs were determined by microdilution and bactericidal activity was determined using time-kill curves. A peritoneal sepsis murine model was used to evaluate the in vivo impact. Bacterial fitness was analysed using growth curves and competition assays. The presence of the aac(6')-Ib-cr gene increased the MICs of ciprofloxacin and norfloxacin 4-8-fold for all E. coli genotypes, independently of the initial resistance level. Combination of the aac(6')-Ib-cr gene with three or four chromosomal mechanisms was necessary to reach MIC values above the susceptible category. Killing curve assays showed a clear selective advantage for survival in strains harbouring the aac(6')-Ib-cr gene (up to 7 log10 cfu/mL after 24 h). AAC(6')-Ib-cr significantly reduced the ciprofloxacin efficacy in vivo. In terms of bacterial fitness cost, maximal OD was significantly lower for all strains harbouring the aac(6')-Ib-cr gene, independently of chromosomal mutations associated. The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo.
27494906	10	23	AAC(6')-Ib-cr	T116,T126	C0051639
27494906	44	55	chromosomal	T026	C0008633
27494906	66	76	mechanisms	T169	C0441712
27494906	80	88	clinical	T080	C0205210
27494906	89	98	quinolone	T109	C0034428
27494906	99	109	resistance	T038	C0013203
27494906	113	129	Escherichia coli	T007	C0014834
27494906	130	143	aac(6')-Ib-cr	T028	C0017337
27494906	166	173	plasmid	T114,T123	C0032136
27494906	184	199	fluoroquinolone	T109,T121	C0949665
27494906	201	203	FQ	T109,T121	C0949665
27494906	205	225	resistance mechanism	T039	C1514892
27494906	229	247	Enterobacteriaceae	T007	C0014346
27494906	296	303	plasmid	T114,T123	C0032136
27494906	314	318	gene	T028	C0017337
27494906	323	334	chromosomal	T026	C0008633
27494906	345	354	quinolone	T109	C0034428
27494906	355	376	resistance mechanisms	T039	C1514892
27494906	385	387	FQ	T109,T121	C0949665
27494906	388	398	resistance	T038	C0013203
27494906	403	412	bacterial	T007	C0004611
27494906	413	420	fitness	T045	C2717776
27494906	424	440	Escherichia coli	T007	C0014834
27494906	442	460	E. coli ATCC 25922	T007	C0014834
27494906	473	489	isogenic strains	T001	C1512692
27494906	499	510	chromosomal	T026	C0008633
27494906	521	530	quinolone	T109	C0034428
27494906	531	541	resistance	T038	C0013203
27494906	542	555	modifications	T063	C4277689
27494906	557	574	Ser83Leu-Asp87Asn	T045	C0026882
27494906	578	582	GyrA	T116,T126	C0949782
27494906	584	592	Ser80Arg	T045	C0026882
27494906	596	600	ParC	T116,T126	C0209525
27494906	610	628	marR gene deletion	T045	C0017260
27494906	635	649	electroporated	T059	C0206691
27494906	657	664	pBK-CMV	T114,T123	C0032136
27494906	665	671	vector	T114	C0017397
27494906	672	680	encoding	T052	C2700640
27494906	681	694	AAC(6')-Ib-cr	T116,T126	C0051639
27494906	700	704	MICs	T034	C1304747
27494906	708	711	FQs	T109,T121	C0949665
27494906	731	744	microdilution	T059	C0201207
27494906	749	770	bactericidal activity	T039	C0544570
27494906	792	808	time-kill curves	T081	C0683162
27494906	812	842	peritoneal sepsis murine model	T008	C0599779
27494906	868	875	in vivo	T082	C1515655
27494906	884	893	Bacterial	T007	C0004611
27494906	894	901	fitness	T045	C2717776
27494906	939	957	competition assays	T059	C0005507
27494906	979	997	aac(6')-Ib-cr gene	T028	C0017337
27494906	1012	1016	MICs	T034	C1304747
27494906	1020	1033	ciprofloxacin	T109,T121	C0008809
27494906	1038	1049	norfloxacin	T109,T195	C0028365
27494906	1067	1074	E. coli	T007	C0014834
27494906	1075	1084	genotypes	T032	C0017431
27494906	1115	1125	resistance	T038	C0013203
27494906	1152	1170	aac(6')-Ib-cr gene	T028	C0017337
27494906	1190	1201	chromosomal	T026	C0008633
27494906	1202	1212	mechanisms	T169	C0441712
27494906	1236	1246	MIC values	T034	C1304747
27494906	1279	1299	Killing curve assays	T081	C0683162
27494906	1339	1347	survival	T052	C0038952
27494906	1351	1358	strains	T080	C0456178
27494906	1374	1392	aac(6')-Ib-cr gene	T028	C0017337
27494906	1428	1441	AAC(6')-Ib-cr	T116,T126	C0051639
27494906	1468	1481	ciprofloxacin	T109,T121	C0008809
27494906	1491	1498	in vivo	T082	C1515655
27494906	1512	1521	bacterial	T007	C0004611
27494906	1522	1534	fitness cost	T045	C2717776
27494906	1579	1586	strains	T080	C0456178
27494906	1602	1620	aac(6')-Ib-cr gene	T028	C0017337
27494906	1639	1660	chromosomal mutations	T049	C0948447
27494906	1677	1695	aac(6')-Ib-cr gene	T028	C0017337
27494906	1729	1739	resistance	T038	C0013203
27494906	1793	1801	clinical	T080	C0205210
27494906	1802	1807	level	T080	C0441889
27494906	1811	1824	ciprofloxacin	T109,T121	C0008809
27494906	1829	1840	norfloxacin	T109,T195	C0028365
27494906	1841	1851	resistance	T038	C0013203
27494906	1886	1907	chromosomal mutations	T049	C0948447
27494906	1914	1922	in vitro	T080	C1533691
27494906	1927	1934	in vivo	T082	C1515655